Europe's opportunity to open up drug regulation

BMJ (Online)

Volumn 340, Issue 7751, 2010, Pages 842-843

  Garattini, Silvio ^a   Bertele', Vittorio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG APPROVAL; DRUG INDUSTRY; DRUG INFORMATION; DRUG LEGISLATION; EUROPE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; PATIENT ASSESSMENT; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

CONFIDENTIALITY; DISCLOSURE; DRUG APPROVAL; DRUG EVALUATION; DRUG INFORMATION SERVICES; EUROPEAN UNION; LEGISLATION, DRUG;

EID: 77951045923     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Godlee F. We want raw data, now. BMJ 2009;339:b5405.
2. Godlee F, Clarke M. Why don't we have all the evidence on oseltamivir? BMJ 2009;339:b5351.
3. O'Reilly JT. Implications of international drug approval system on confidentiality of business secrets in the U.S. pharmaceutical industry. Intern Drug Approval Syst 1998;53:123-132
4. Garattini S, Chalmers I. Patients and the public deserve big changes in evaluation of drugs. BMJ 2009;338:b1025.
5. Vitry A, Bertele' V, Garattini S. Drug regulation and the need for greater transparency. RAJ Pharma 2009;March:1-4.
6. European Medicines Agency. Draft budget for 2010. www.ema.europa.eu/pdfs/ general/manage/MB2009/meeting65/70012409en.pdf.
7. US Food and Drug Administration. Performance budget overview. www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/BudgetReports/ 2007FDABudgetSummary/UCM121013.pdf.
8. Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ 1997;315:640-645
9. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003;326:1171-1173 (Pubitemid 36649049)
10. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. Plos Med 2008;5:e45.
11. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291:2457-2465 (Pubitemid 38669189)
12. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021-2029